

## References

I-88

1. Neupogen (filgrastim) injection, for subcutaneous or intravenous use [package insert]. Amgen Inc. Thousand Oaks, CA. Revised 06/2018.
2. Granix (tbo-filgrastim) injection, for subcutaneous use [package insert]. Teva Pharmaceuticals USA, Inc. North Wales, PA. Revised 11/2019.
3. National Comprehensive Cancer Network (NCCN). NCCN Drugs & Biologics Compendium®. Tbo-filgrastim. 2020.
4. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in Myeloid growth factors. Version 1.2018.
5. Smith TJ, Bohlke K, Lyman GH, et al. American Society of Clinical Oncology. Recommendations for the use of WBC growth factors: American Society of Clinical Oncology clinical practice guideline update. *J Clin Oncol*. 2015;33(28):3199-3212.
6. Pettengell R, Bias P, Mueller U, et al. Clinical safety of tbo-filgrastim, a short-acting human granulocyte colony-stimulating factor. *Supportive Care In Cancer: Official Journal Of The Multinational Association Of Supportive Care In Cancer*. 2016;24(6):2677-2684.
7. Gascón P, Aapro M, Gascón P, et al. Treatment patterns and outcomes in the prophylaxis of chemotherapy-induced (febrile) neutropenia with biosimilar filgrastim (the MONITOR-GCSF study). *Supportive Care In Cancer*. 2016;24(2):911-925.
8. Brito M, Esteves S, André R, et al. Comparison of effectiveness of biosimilar filgrastim (Nivestim™), reference Amgen filgrastim and pegfilgrastim in febrile neutropenia primary prevention in breast cancer patients treated with neo(adjuvant) TAC: A non-interventional cohort study. *Supportive Care In Cancer: Official Journal Of The Multinational Association Of Supportive Care In Cancer*. 2016;24(2):597-603.
9. Leukine (sargramostim) injection, for subcutaneous or intravenous use [package insert]. Partner Therapeutics, Inc. Lexington, MA. Revised 05/2018.
10. Neulasta (pegfilgrastim) injection, for subcutaneous use [package insert]. Amgen Inc. Thousand Oaks, CA. Revised 01/2020.
11. Zarxio (filgrastim-sndz) injection, for subcutaneous or intravenous use [package insert]. Sandoz Inc. Princeton, NJ. Revised 08/2019.
12. National Comprehensive Cancer Network (NCCN). Filgrastim. NCCN Drugs and Biologics Compendium®. 2020.
13. National Comprehensive Cancer Network (NCCN). Filgrastim-sndz. NCCN Drugs and Biologics Compendium®. 2020.

14. National Comprehensive Cancer Network (NCCN). Pegfilgrastim. NCCN Drugs and Biologics Compendium®. 2020.
15. National Comprehensive Cancer Network (NCCN). Sargramostim. NCCN Drugs and Biologics Compendium®. 2020.
16. National Comprehensive Cancer Network (NCCN). Filgrastim-aafi. NCCN Drugs and Biologics Compendium®. 2020.
17. National Comprehensive Cancer Network (NCCN). Pegfilgrastim-bmez. NCCN Drugs and Biologics Compendium®. 2020.
18. National Comprehensive Cancer Network (NCCN). Pegfilgrastim-jmdb. NCCN Drugs and Biologics Compendium®. 2020.
19. National Comprehensive Cancer Network (NCCN). Pegfilgrastim-cbqv. NCCN Drugs and Biologics Compendium®. 2020.
20. Filgrastim. Clinical Pharmacology Compendia. Tampa FL: Gold Standard, Inc. 2020.
21. Filgrastim-sndz. Clinical Pharmacology Compendia. Tampa FL: Gold Standard, Inc. 2020.
22. Pegfilgrastim. Clinical Pharmacology Compendia. Tampa FL: Gold Standard, Inc. 2020.
23. Tbo-filgrastim. Clinical Pharmacology Compendia. Tampa FL: Gold Standard, Inc. 2020.
24. Sargramostim. Clinical Pharmacology Compendia. Tampa FL: Gold Standard, Inc. 2020.
25. Clinical Pharmacology Compendia [database online]. Tampa FL: Gold Standard, Inc. Filgrastim-aafi. 2020.
26. Clinical Pharmacology Compendia [database online]. Tampa FL: Gold Standard, Inc. Pegfilgrastim-bmez. 2020.
27. Clinical Pharmacology Compendia [database online]. Tampa FL: Gold Standard, Inc. Pegfilgrastim-jmdb. 2020.
28. Clinical Pharmacology Compendia [database online]. Tampa FL: Gold Standard, Inc. Pegfilgrastim-cbqv. 2020.
29. MICROMEDEX®SOLUTIONS Compendia. 2020.Filgrastim.
30. MICROMEDEX®SOLUTIONS Compendia. 2020.Filgrastim-sndz.
31. MICROMEDEX®SOLUTIONS Compendia. 2020.Pegfilgrastim.
32. MICROMEDEX®SOLUTIONS Compendia. 2020.Tbo-filgrastim.
33. MICROMEDEX®SOLUTIONS Compendia.2020.Sargramostim.

34. MICROMEDEX®SOLUTIONS Compendia. 2020. Filgrastim-aafi.
35. MICROMEDEX®SOLUTIONS Compendia. 2020. Pegfilgrastim-bmez.
36. MICROMEDEX®SOLUTIONS Compendia. 2020. Pegfilgrastim-jmdb.
37. MICROMEDEX®SOLUTIONS Compendia. 2020. Pegfilgrastim-cbqv.
38. Douglas AG, Schwab P, Lane D, Kennedy K, Slabaugh SL, and Bowe A. A comparison of brand and biosimilar granulocyte-colony stimulating factors for prophylaxis of chemotherapy-induced febrile neutropenia. *J Manage Care Spec Pharm*. 2017;23(12):1221-1226.
39. Weycker D, Li X, Tzivelekis S, Atwood M, Garcia J, Li Y, et al. Burden of chemotherapy-induced febrile neutropenia hospitalizations in US clinical practice, by use and patterns of prophylaxis with colony-stimulating factor. *Support Care Cancer*. 2017;25:439-447.
40. Fulphila (pegilgrastim-jmdb) injection, for subcutaneous use [package insert]. Mylan Institutional LLC. Rockford, IL. Revised 05/2019.
41. Filgrastim-aafi (Nivestym™) for subcutaneous or intravenous injection [package insert]. Lake Forest, IL. Hospira Inc., a Pfizer Company. Revised 07/2018.
42. Federman N, Dragomir MD, Kizyma Z, Lebedev V, Roganovic J, Bias P, et al. A phase 2, international, multicenter, prospective clinical trial of subcutaneous tbo-filgrastim in pediatric patients with solid tumors undergoing chemotherapy. *Blood*. 2017;130:2271.
43. Udenyca (pegfilgrastim-cbqv) injection, for subcutaneous use [package insert]. Coherus BioSciences, Inc. Redwood City, CA. Revised 09/2019.
44. Nakov R, Gattu S, Wang J, Velinova M, Schaffar G, & Skerjanec A. Proposed biosimilar pegfilgrastim shows similarity in pharmacokinetics and pharmacodynamics to reference pegfilgrastim in healthy subjects. *J Clin Pharmacol*. 2018;84(12):2790-2801.
45. Ziextenzo™(pegfilgrastim-bmez) injection, for subcutaneous use [package insert]. Sandoz, Inc. Princeton, NJ. Revised 11/2019.
46. Kuan JW, Su AT, Leong CF. Pegylated granulocyte-colony stimulating factor versus non-pegylated granulocyte-colony stimulating factor for peripheral blood stem cell mobilization: A systematic review and meta-analysis. *Journal of Clinical Apheresis*. 2017;32(6):517-542.
47. Halim LA, Márquez M, Maas-Bakker RF, Castañeda-Hernández G, Jiskoot W, Schellekens H. Quality comparison of biosimilar and copy filgrastim products with the innovator product. *Pharmaceutical Research*. 2018;35(11):1-12.
48. Nyvepria™(pegfilgrastim-apgf) injection, for subcutaneous use [package insert]. Hospira, Inc. Lake Forest, IL. Revised 06/2020.
49. National Comprehensive Cancer Network (NCCN). Pegfilgrastim-apgf. NCCN Drugs and Biologics Compendium®. 2020.